Aralez Pharmaceuticals

Aralez Pharmaceuticals products

Fibricor (fenofibric acid)
Indication: Adjunct to diet for treatment of severe hypertriglyceridemia and for reducing elevated LDL-C, total cholesterol, triglycerides, and Apo B; also increases HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia
Status: Marketed in the U.S.

Toprol-XL (metoprolol succinate ER)
Indication: Hypertension, long-term treatment of angina pectoris, and stable NYHA class II or III heart failure
Status: Acquired U.S. rights; extended-release oral tablet formulation; marketed in the U.S.

Yosprala (aspirin + omeprazole DR tablet)
Indication: Secondary prevention of cardiovascular or cerebrovascular events in patients at risk of aspirin-associated gastric ulcers; delivers immediate-release omeprazole followed by delayed-release enteric-coated aspirin
Status: Marketed in the U.S. with multiple formulations (e.g., 81/40 mg, 325/40 mg)

Zontivity (vorapaxar)
Indication: Reduction of thrombotic cardiovascular events in patients with prior myocardial infarction or peripheral arterial disease; used in combination with aspirin and/or clopidogrel
Status: Marketed in the U.S.

Treximet (naproxen/sumatriptan) (also known as Suvexx in Canada)
Indication: Acute treatment of migraine attacks
Status: Marketed; available in U.S. and Canadian markets under respective brand names

Vimovo (esomeprazole/naproxen)
Indication: Provides gastrointestinal protection alongside NSAID therapy; combines a PPI with naproxen
Status: Rights transferred (no longer held); previously part of product portfolio

Cambia (diclofenac potassium oral solution)
Indication: Acute treatment of migraine attacks (only prescription NSAID for migraines available in Canada)
Status: Marketed in Canada

Blexten (bilastine)
Indication: Second-generation oral antihistamine for allergic conditions
Status: Marketed in Canada

Suvexx (brand name for Treximet in Canada)
Indication: Migraine treatment
Status: Marketed in Canada

Resultz (isopropyl myristate)
Indication: Topical dermatologic product
Status: Marketed in Canada under the Aralez legacy portfolio

NeoVisc (sodium hyaluronate 1%)
Indication: Joint lubrication for symptomatic relief, e.g., in osteoarthritis
Status: Marketed in Canada

Uracyst (sodium chondroitin sulfate 2%)
Indication: Treatment related to urinary tract conditions
Status: Marketed in Canada

Durela (tramadol hydrochloride)
Indication: Pain management
Status: Marketed in Canada

Proferrin (heme iron polypeptide)
Indication: Iron supplementation (for iron deficiency)
Status: Marketed in Canada

Collatamp G (collagen–gentamicin)
Indication: Local antibiotic delivery in surgical sites
Status: Marketed in Canada